PMID- 25228592 OWN - NLM STAT- MEDLINE DCOM- 20150713 LR - 20211021 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 5 IP - 20 DP - 2014 Oct 30 TI - Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. PG - 9609-18 AB - The development of novel therapies against melanoma would benefit from individualized tumor models to ensure the rapid and accurate identification of biomarkers of therapy response. Previous studies have suggested that patient-derived xenografts (PDXes) could be useful. However, the utility of PDXes in guiding real-time treatment decisions has only been reported in anecdotal forms. Here tumor biopsies from patients with stage III and IV metastatic malignant melanoma were transplanted into immunocompromised mice to generate PDXes. 23/26 melanoma biopsies generated serially transplantable PDX models, and their histology, mutation status and expression profile resembled their corresponding patient biopsy. The potential treatment for one patient was revealed by an in vitro drug screen and treating PDXes with the MEK inhibitor trametinib. In another patient, the BRAF mutation predicted the response of both the patient and its corresponding PDXes to MAPK-targeted therapy. Importantly, in this unselected group of patients, the time from biopsy for generation of PDXes until death was significantly longer than the time required to reach the treatment phase of the PDXes. Thus, it could be clinically meaningful to use this type of platform for melanoma patients as a pre-selection tool in clinical trials. FAU - Einarsdottir, Berglind O AU - Einarsdottir BO AD - Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. FAU - Bagge, Roger Olofsson AU - Bagge RO AD - Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. FAU - Bhadury, Joydeep AU - Bhadury J AD - Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. FAU - Jespersen, Henrik AU - Jespersen H AD - Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. FAU - Mattsson, Jan AU - Mattsson J AD - Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. FAU - Nilsson, Lisa M AU - Nilsson LM AD - Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. FAU - Truve, Katarina AU - Truve K AD - The Bioinformatics Core Facility at the University of Gothenburg, Gothenburg, Sweden. FAU - Lopez, Marcela Davila AU - Lopez MD AD - Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. The Bioinformatics Core Facility at the University of Gothenburg, Gothenburg, Sweden. FAU - Naredi, Peter AU - Naredi P AD - Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. FAU - Nilsson, Ola AU - Nilsson O AD - Department of Biomedicine, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. FAU - Stierner, Ulrika AU - Stierner U AD - Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. FAU - Ny, Lars AU - Ny L AD - Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. FAU - Nilsson, Jonas A AU - Nilsson JA AD - Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Sahlgrenska Translational Melanoma Group at the Sahlgrenska Cancer Center, Gothenburg, Sweden. LA - eng PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Animals MH - Female MH - Humans MH - Lymphatic Metastasis MH - Male MH - Melanoma/*drug therapy/genetics/*pathology MH - Mice MH - Mice, Knockout MH - Middle Aged MH - Precision Medicine MH - Skin Neoplasms/*drug therapy/genetics/*pathology MH - Xenograft Model Antitumor Assays/*methods PMC - PMC4259423 COIS- Conflict of interest The authors have no conflict of interest to declare. EDAT- 2014/09/18 06:00 MHDA- 2015/07/15 06:00 PMCR- 2014/10/01 CRDT- 2014/09/18 06:00 PHST- 2014/09/18 06:00 [entrez] PHST- 2014/09/18 06:00 [pubmed] PHST- 2015/07/15 06:00 [medline] PHST- 2014/10/01 00:00 [pmc-release] AID - 2445 [pii] AID - 10.18632/oncotarget.2445 [doi] PST - ppublish SO - Oncotarget. 2014 Oct 30;5(20):9609-18. doi: 10.18632/oncotarget.2445.